Workflow
Thalys(603716)
icon
Search documents
塞力医疗(603716) - 关于完成工商变更登记并换发营业执照的公告
2026-01-14 08:30
二、工商变更登记情况 公司于近日完成了经营范围的工商变更及《公司章程》的备案手续,并取得 了武汉市东西湖区行政审批局换发的《营业执照》。 | 证券代码:603716 | 证券简称:塞力医疗 | 公告编号:2026-005 | | --- | --- | --- | | 债券代码:113601 | 债券简称:塞力转债 | | 塞力斯医疗科技集团股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 一、基本情况 塞力斯医疗科技集团股份有限公司(以下简称"公司")于 2026 年 1 月 7 日召开 2026 年第一次临时股东会,审议通过了《关于增加公司经营范围及相应 修订<公司章程>的议案》。具体内容详见公司于 2025 年 12 月 23 日在上海证券 交易所网站(www.sse.com.cn)披露的《关于增加公司经营范围及相应修订<公司 章程>的公告》(公告编号:2025-101)。 经营范围:一般项目:第一类医疗器械销售,第一类医疗设备租赁,第二类 医疗器械销售,第二类医疗设 ...
塞力医疗1月13日龙虎榜数据
Group 1 - The stock of Saily Medical (603716) decreased by 0.96% today, with a turnover rate of 31.31% and a trading volume of 1.947 billion yuan, showing a fluctuation of 16.53% [2] - The stock was listed on the Shanghai Stock Exchange's "Dragon and Tiger List" due to its high turnover rate, with a net sell of 30.5364 million yuan from the Shanghai-Hong Kong Stock Connect [2] - Over the past six months, the stock has appeared on the Dragon and Tiger List 18 times, with an average price increase of 3.44% the day after being listed and an average increase of 11.40% in the following five days [2] Group 2 - The company's Q3 report for 2025 revealed a total revenue of 857 million yuan for the first three quarters, representing a year-on-year decline of 39.64%, and a net loss of 87.2441 million yuan [2] - The main capital outflow for the stock today was 60.3619 million yuan, with a significant outflow of 21.9535 million yuan from large orders and 38.4084 million yuan from major orders [2] - In the last five days, the stock has seen a total net outflow of 67.7795 million yuan [2]
塞力医疗股价涨5.12%,广发基金旗下1只基金位居十大流通股东,持有122.36万股浮盈赚取182.31万元
Xin Lang Cai Jing· 2026-01-13 03:42
Group 1 - The core point of the news is that Sely Medical has seen a significant stock price increase of 5.12% on January 13, reaching 30.58 CNY per share, with a total market capitalization of 6.428 billion CNY and a trading volume of 862 million CNY, indicating a 20.01% cumulative increase over three consecutive days [1] - Sely Medical, established on February 23, 2004, and listed on October 31, 2016, is based in Wuhan, Hubei Province, and specializes in medical testing services, agency of in vitro diagnostic products, and the research, production, and sales of its own in vitro diagnostic products [1] - The company's main business revenue composition includes IVD business at 39.91%, SPD business at 38.01%, and pure sales at 22.08% [1] Group 2 - From the perspective of Sely Medical's top ten circulating shareholders, a fund under GF Fund ranks among them, specifically the GF Healthcare Stock A (004851), which entered the top ten shareholders in the third quarter with 1.2236 million shares, accounting for 0.58% of circulating shares [2] - The GF Healthcare Stock A fund has a current scale of 5.185 billion CNY and has achieved a year-to-date return of 10.14%, ranking 1178 out of 5517 in its category, with a one-year return of 25.72%, ranking 3223 out of 4203 [2] - The fund manager, Wu Xingwu, has been in position for 10 years and 339 days, overseeing a total fund asset scale of 10.641 billion CNY, with the best fund return during his tenure being 102.67% and the worst being -38.11% [2]
股市必读:塞力医疗(603716)登1月12日交易所龙虎榜
Sou Hu Cai Jing· 2026-01-12 17:14
截至2026年1月12日收盘,塞力医疗(603716)报收于29.09元,上涨4.53%,换手率32.78%,成交量68.9万 手,成交额19.36亿元。 当日关注点 交易信息汇总资金流向 1月12日主力资金净流出3448.45万元,占总成交额1.78%;游资资金净流入362.04万元,占总成交额 0.19%;散户资金净流入3086.41万元,占总成交额1.59%。 龙虎榜上榜 沪深交易所2026年1月12日公布的交易公开信息显示,塞力医疗(603716)因有价格涨跌幅限制的日换 手率达到20%的前五只证券登上龙虎榜。此次是近5个交易日内第4次上榜。 以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成 投资建议。 来自交易信息汇总:1月12日塞力医疗主力资金净流出3448.45万元,占总成交额1.78%。 来自交易信息汇总:塞力医疗因日换手率达20%于1月12日登龙虎榜,近5个交易日内第4次上榜。 ...
塞力医疗龙虎榜数据(1月12日)
塞力医疗1月12日交易公开信息 具体来看,今日上榜的营业部中,共有1家机构专用席位现身,即买三,合计净买入2536.87万元,沪股 通为第一大买入营业部及第一大卖出营业部,买入金额为2969.40万元,卖出金额为6928.18万元,合计 净卖出3958.78万元。 近半年该股累计上榜龙虎榜17次,上榜次日股价平均涨3.72%,上榜后5日平均涨12.38%。 资金流向方面,今日该股主力资金净流出5115.44万元,其中,特大单净流出2142.48万元,大单资金净 流出2972.95万元。近5日主力资金净流入6337.74万元。 2025年10月30日公司发布的三季报数据显示,前三季度公司共实现营业收入8.57亿元,同比下降 39.64%,实现净利润-8724.41万元。(数据宝) 塞力医疗(603716)今日上涨4.53%,全天换手率32.78%,成交额19.36亿元,振幅12.69%。龙虎榜数据显 示,机构净买入2536.87万元,沪股通净卖出3958.78万元,营业部席位合计净卖出1217.18万元。 上交所公开信息显示,当日该股因日换手率达32.78%上榜,机构专用席位净买入2536.87万元,沪股通 净 ...
医药商业板块1月12日涨0.8%,润达医疗领涨,主力资金净流出2.34亿元
Market Performance - The pharmaceutical commercial sector increased by 0.8% on January 12, with RunDa Medical leading the gains [1] - The Shanghai Composite Index closed at 4165.29, up 1.09%, while the Shenzhen Component Index closed at 14366.91, up 1.75% [1] Top Gainers - RunDa Medical (603108) closed at 19.47, up 8.53%, with a trading volume of 1.0956 million shares and a transaction value of 2.123 billion [1] - Jia Shi Tang (002462) closed at 17.13, up 6.33%, with a trading volume of 441,200 shares and a transaction value of 733 million [1] - Yao Yi Gou (300937) closed at 38.42, up 4.54%, with a trading volume of 127,500 shares and a transaction value of 480 million [1] Top Losers - Nanjing Pharmaceutical (600713) closed at 5.43, down 1.63%, with a trading volume of 284,200 shares and a transaction value of 154 million [2] - Zhong Yao Holdings (000950) closed at 6.24, down 1.11%, with a trading volume of 740,900 shares and a transaction value of 461 million [2] - Ying Te Group (000411) closed at 12.81, down 1.08%, with a trading volume of 187,000 shares and a transaction value of 239 million [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 234 million from institutional investors and 184 million from speculative funds, while retail investors saw a net inflow of 417 million [2] - RunDa Medical had a net inflow of 123 million from institutional investors, but a net outflow of 171 million from speculative funds [3] - Jia Shi Tang experienced a net inflow of 80.845 million from institutional investors, with a net outflow of 28.7836 million from speculative funds [3]
脑机接口概念股走强,爱朋医疗涨超9%
Ge Long Hui· 2026-01-12 06:37
Group 1 - The A-share market saw a strong performance in brain-computer interface concept stocks, with several companies approaching or hitting their daily limit up [1] - Notable gainers included Entropy Technology, which approached a 20% limit up, and Dao's Technology and Yingkang Life, both rising over 13% [1] - Other significant performers included Tom Cat, which increased by over 10%, and Yanshan Technology, which hit a 10% limit up [1] Group 2 - The table lists various companies with their respective stock codes, percentage increase, total market capitalization, and year-to-date performance [2] - Entropy Technology (301330) had a 19.40% increase, with a market cap of 11.7 billion and a year-to-date increase of 50.11% [2] - Dao's Technology (300409) rose by 13.91%, with a market cap of 25.9 billion and a year-to-date increase of 47.49% [2] - Yingkang Life (300143) increased by 13.01%, with a market cap of 10 billion and a year-to-date increase of 35.43% [2] - Other companies like Tom Cat (300459) and Yanshan Technology (002195) also showed significant gains, with year-to-date increases of 29.63% and 60.65% respectively [2]
A股脑机接口概念股走强,爱朋医疗涨超9%
Ge Long Hui A P P· 2026-01-12 06:31
Core Viewpoint - The A-share market has seen a strong performance in brain-computer interface concept stocks, with several companies approaching or hitting their daily price limits [1] Group 1: Stock Performance - Entropy Technology (熵基科技) approached a 20% daily limit increase, with a rise of 19.40% and a market capitalization of 11.7 billion [2] - Dao's Technology (道氏技术) increased by 13.91%, reaching a market cap of 25.9 billion [2] - Yingkang Life (盈康生命) rose by 13.01%, with a market cap of 10 billion [2] - Tom Cat (汤姆猫) saw a 10.19% increase, with a market cap of 20.9 billion [2] - Rock Mountain Technology (岩山科技) hit a 10% daily limit increase, with a market cap of 64.6 billion [2] - Three Seven Entertainment (三七互娱) approached a 10% daily limit increase, with a rise of 9.97% and a market cap of 66.4 billion [2] - Other notable performers include Aipeng Medical (爱朋医疗) at 9.99%, Lens Technology (蓝思科技) at 9.80%, and Nanjing Panda (南京熊猫) at 9.33% [2] Group 2: Year-to-Date Performance - Entropy Technology has a year-to-date increase of 50.11% [2] - Dao's Technology has risen 47.49% year-to-date [2] - Yingkang Life has a year-to-date increase of 35.43% [2] - Tom Cat has increased by 29.63% year-to-date [2] - Rock Mountain Technology has a significant year-to-date increase of 60.65% [2] - Aipeng Medical has a year-to-date increase of 54.31% [2] - Nanjing Panda has a remarkable year-to-date increase of 63.01% [2] - Other companies like Innovation Medical (创新医疗) and Keda Xunfei (科大讯飞) have year-to-date increases of 74.01% and 19.29%, respectively [2]
塞力医疗:截至2025年12月31日股东总户数66905户
Zheng Quan Ri Bao Wang· 2026-01-09 13:40
证券日报网讯1月9日,塞力医疗(603716)在互动平台回答投资者提问时表示,截至2025年12月31日, 公司股东总户数66905户。 ...
多股涨超10%!“阿福概念”走强
Group 1 - The AI healthcare sector showed strong performance on January 9, with multiple stocks experiencing significant gains, including Meinian Health (002044) hitting the daily limit, and Dean Diagnostics (300244) also reaching a "20CM" limit up [1] - The driving force behind this market movement is attributed to the announcement by OpenAI on January 8 regarding the launch of "ChatGPT Health," which offers health consultation and management services, seen as a direct competition to Ant Group's AI health application "Antifufu" [1] - "Antifufu" reported over 30 million monthly active users and more than 10 million daily health inquiries within a month of its latest version release, indicating high user acceptance and significant market potential for health AI in China [1] Group 2 - The capital market reacted quickly, with stocks like Yuyue Medical and Weining Health experiencing an initial rise following the release of the new version of "Antifufu" in December [2] - Companies such as Yuyue Medical and Sanofi Bio confirmed their collaboration with "Antifufu," reinforcing market expectations for industry chain synergy [2] - Industry experts believe that as domestic and international tech leaders invest heavily, the application of AI in healthcare will accelerate from the exploration phase to practical implementation, benefiting companies with established scenarios and clear commercialization paths [2]